Abstract Classical Hodgkin Lymphoma is distinguished from other lymphomas by its peculiar
biology and heterogeneous chemosensitivity. Most of the patients respond to the standard …

Our group has recently demonstrated that chimeric antigen receptor T-cell therapy targeting
the CD30 antigen (CD30. CAR-T) is highly effective in patients with relapsed and refractory …

Lymphomas are the most common hematological malignancies and are further
distinguished in Hodgkin lymphoma (HL) and non-Hodgkin (NHL). For staging purposes …

Consensus about a standard segmentation method to derive metabolic tumor volume (MTV)
in classical Hodgkin lymphoma (cHL) is lacking, and it is unknown how different …

Risk-stratified treatment strategies have the potential to increase survival and lower toxicity
in relapsed/refractory classical Hodgkin lymphoma (R/R cHL) patients. This study …

Elderly Hodgkin lymphoma (HL) is an aggressive lymphoma subgroup with high 18F-FDG
avidity at 18F-FDG-PET/CT but no shared criteria for PET/CT in treatment evaluation and …

Hodgkin lymphoma (HL) is a hematological malignancy with an excellent prognosis.
However, we still need to identify those patients that could experience failed standard …

Background Autologous stem cell transplantation (ASCT) is the standard treatment strategy
for refractory or relapsed classical Hodgkin lymphoma (R/R cHL). However, a single …

Introduction Functional metabolic imaging with 18 F-fluorodeoxyglucose positron emission
tomography combined with computed tomography (PET/CT) is considered the gold standard …

Hodgkin lymphoma (HL) has a bimodal age distribution curve, with a second peak in people
aged more than 60 years. Interim PET/CT (iPET/CT) is highly predictive for PFS and OS in …